INTRODUCTION
Prostaglandins (PGs) appear to exert an inhibitory effect on insulin secretion from pancreatic islets, in light of the evidence that the inhibition of PG synthesis augments glucose-stimulated insulin release from isolated islets (Robertson, 1983; Turk et al., 1988) and increases plasma insulin in diabetics exposed to a glucose challenge (Robertson & Chen, 1977) . Exogenous PGE also inhibits insulin release from dog pancreas (Robertson, 1974) and insulinoma cells (Robertson et al., 1987) , although stimulatory effects of PGs on insulin release have also been reported (Pek et al., 1978 (Pek et al., , 1980 Matsuyama et al., 1983) . The cellular mechanisms accounting for the PG effects appear to be complex. Although PGE2 inhibits adenylate cyclase in insulinoma cells (Robertson et al., 1987) , it also inhibits glucose oxidation in islets (Laychock, 1989) . The last two reports link the effect of PGE2 to a transduction mechanism(s) modulated by a guaninenucleotide-binding regulatory (G) protein which is sensitive to pertussis toxin.
Among its many actions, glucose is known to promote phosphoinositide hydrolysis (Laychock, 1983) and the production of inositol phosphates (InsPs) in pancreatic islets (Best & Malaisse, 1984; Turk et al., 1986) , which may participate in Ca21 mobilization and insulin release (Wolf et al., 1985; Wollheim et al., 1986) . Moreover, a G-protein mediates the activation of phospholipase C and InsPs production in the islet (Dunlop & Larkins, 1986; Blachier & Malaisse, 1987 Pancreatic islets were isolated from excised pancreata of male Sprague-Dawley rats by collagenase digestion, as described previously (Hoffman & Laychock, 1988 (Robertson et al., 1987 (Blachier & Malaisse, 1987; Cockcroft & Stutchfield, 1988 Vol. 260 (Robertson, 1974 (Robertson, , 1983 Turk et al., 1988; Laychock & Bilgin, 1989) . The negative influence of PGE2 on insulin release appears to be modulated in part by the receptor-mediated inhibition of adenylate cyclase (Robertson et al., 1987) . PGE2 (1 /tM) causes maximum inhibition of cyclic AMP production (Robertson et al., 1987 ). An inhibitory G-protein mediates the inhibitory effects of PGE on insulin release, since pertussis toxin reverses the inhibitory response in islets and insulinoma cells (Robertson et al., 1987) . However, PGE2 also inhibits glucose oxidation, and a pertussis-toxin-inhibitable process modulates the glucose-oxidation response (Laychock, 1989; Laychock & Bilgin, 1989) . Since glucose utilization in islets is not modulated by cyclic AMP (Laychock, 1987) , PGE2 may have an effect on a transduction mechanism(s) other than adenylate cyclase which modulates metabolism and insulin release. The responses of [3H]InsPs production, glucose utilization and insulin secretion to PGE2 have certain characteristics in common. PGE2 synthesis increases gradually after a glucose stimulus (Kelly & Laychock, 1984; Robertson et al., 1987) , and suppresses the secondary phase of insulin secretion (Robertson & Chen, 1977; Evans et al., 1983) , suggesting that PGE2 may act as a negative-feedback inhibitor of insulin secretion. It is not known why the inhibitory effects of PGE2 on [3H]InsPs accumulation and glucose utilization (Laychock, 1989 ) require a period of pre-exposure to PGE2. Perhaps the binding of PGE2 to its receptor is ratelimiting, or PGE is metabolized to prostaglandyl-inositol cyclic phosphate (Partke & Wasner, 1986) , which inhibits protein phosphorylation in islets. The latent response to PGE2 supports its role as a negative-feedback modulator of the insulin-secretory response. The relationship between glucose utilization and [3H]InsPs levels has not been defined, except that polyphosphoinositide hydrolysis is dependent on glucose metabolism (Laychock, 1983) . The inhibitory effects of PGE2 on [3H]InsPs accumulation may be indirectly mediated by changes in glucose metabolism. Alternatively, polyphosphoinositide hydrolysis to diacylglycerol and InsPs stimulates protein kinase C and Ca2+ mobilization, respectively, which may modulate directly or indirectly the activity of glucose-metabolic pathways and insulin release.
